In previous studies we demonstrated telomerase activity in frozen tissues from BCC and their tumor-free margins by the PCR ELISA. In this study we examined in the same frozen sections immunohistochemical presence of hTERT in the nucleus. After fixation in acetone and methanol followed by steaming we used for visualization the antigenantibody reactions by APAAP. This was the best method of preparation of the frozen sections in our preliminary hTERT-study with squamous cell carcinomas. This study was supplemented with antibodies against Ki-67, nucleolin, common leucocyte antigen CD45 and mutated p53. The immunoreactive scores were determined and included the comparison with telomerase activity. The investigation of hTERT expression was performed in the tissues of 41 patients with BCC and control tissues of 14 patients without tumor. Eleven commercial antibodies were used for a nuclear staining of hTERT expression. With the anti-hTERT antibodies we looked for both satisfactory distribution and intensity of immunohistochemical labeling in the carcinomas and in the squamous epithelia of the tumor centers, of the tumor-free margins and of the control tissues. The hTERT expression in the BCC was distributed heterogeneously. The score values established by the anti-hTERT antibodies used were variably or significantly increased. In the stroma they tended to be negative, so we disregarded stroma hTERT. Proof of hTERT did not differ uniformly from telomerase activity. We compared the high with the lower median hTERT values in the Kaplan-Meier curve. Patients with lower hTERT scores in the center or tumor margin as shown by some of the antibodies suffered relapse earlier. Finally, we compared the hTERT expression in BCC tissues with the hTERT scores in HNSCC tissues from our previous study. Only one anti-hTERT antibody (our Ab 7) yielded significantly higher scores in BCC than in HNSCC.
Introduction
In recent years basal cell carcinomas (BCC) have been the most frequent non-melanoma skin tumors (1-10) world-wide and their incidence is increasing each year. Epidemiological data (5, 6, 8, 9, (11) (12) (13) (14) (15) (16) show clearly that ultraviolet (UV) radiation, particularly UVB, is an essential etiological factor in the carcinogenesis of skin tumors. UV exposure is a chronic oxidative stress (17) that causes DNA damage with specific mutations of suppressor genes such as p53 (14, 16, (18) (19) (20) (21) (22) : it is activated along with telomerase (23) (24) (25) (26) (27) . Molecular changes in the skin are associated with local cell proliferation. BCCs are characterized by a high rate of loco-regional recurrence and secondary tumors. An important cause of this is field cancerization (28) in the area around the BCC (29) (30) (31) (32) . Studies are in progress to find the best suited molecular or immunohistochemical markers for characterizing tumor-free margin tissue (8, 12, 13, 24, (33) (34) (35) (36) .
Since the development of the TRAP (telomeric repeat amplification protocol) by Kim et al (37) it is possible to demonstrate telomerase activity in many tumors in larger studies. Many investigations have demonstrated telomerase activity in basal cell carcinomas and their tumor margins (23) (24) (25) (26) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) . In our BCC-study we looked for a difference in telomerase activity between BCC-free tumor margin tissue of head and neck tumors, the tumor itself and control tissue (24, 26, 49) . Proof of telomerase by PCR provides no information about telomerase expression in the isolated cells, but immunohistochemistry is well suited for the in situ presentation of telomerase positive cells, providing that INTERNATIONAL JOURNAL OF ONCOLOGY 35: 1377 ONCOLOGY 35: -1394 ONCOLOGY 35: , 2009 Localization of telomerase hTERT protein in frozen sections of basal cell carcinomas (BCC) and tumor margin tissues suitable antibodies are available. This prompted us in the present study to subject the same frozen tissues in which we had demonstrated telomerase activity by PCR ELISA to an immunohistochemical investigation to find out specifically which cells express the catalytic protein subunit of telomerase, hTERT (human telomerase reverse transcriptase).
As for the in situ proof of hTERT in frozen sections of squamous cell carcinoma (SCC) tissues in the head-neck region (52) , hTERT evidence in cryo sections of BCCs was presented using 11 commercial antibodies to hTERT for appropriate nuclear demonstration of hTERT in BCC tissues.
Patients and methods
Collection of tissue samples. For all tissues in our study we obtained the consent previously of the patients who were in our clinic for diagnostics and therapy in the period between 1994 and 2004: 50 basal cell carcinoma specimens from 41 patients and 14 extraoral control samples from 14 patients without tumor in that period. Control tissue collected from younger patients was also taken with previous consent from their parents.
The entire frozen section series was examined by a tumor pathologist (G.P. Wildner) with conventional hemalaun-eosin staining to ensure that carcinoma was present in all tumor center tissue specimens and that the tumor margins were all tumor-free.
BCC tissues. We examined tissue from various locations and with various histopathologies from 26 male patients (63%) aged 62±14 years and 15 female patients (37%) aged 70±17 years. They were classified according to Soyer and Rippey (53, 54) . All tumor samples originated from non-covered areas of the head or the upper trunk. We examined tissue from 25 tumor centers and 25 tumor-free margins. In the tumor center, carcinoma and squamous epithelium were evaluated; in the tumor margin squamous epithelium as well as stroma were examined. The patient data are summarized in Table I .
Patients without cancer and control tissue specimens. For a more critical evaluation of hTERT expression in carcinoma tissues we examined extraoral control tissue without tumor from different locations in the head-neck region from our clinic in the period from 1994 to 2004: 9 males aged 29±17 years and 5 females aged 34±21 years. In the control tissue sections we evaluated hTERT in squamous epithelium. We examined extraoral tissues from the eye (1x), nose (3x), ear (4x), skin (2x), lips (1x) scalp (2x) and forehead (1x). The tissues were taken with the patients' consent in the context of therapy in our clinic.
Immunohistochemistry and immunoreactive score values (IRS).
We used the frozen sections from basal cell carcinomas in which we had previously demonstrated telomerase activity in PCR ELISA (24, 49) . As already reported (52), we optimized nuclear hTERT demonstration by working with four commercially available anti-hTERT antibodies, the three polyclonal rabbit antibodies, code PC 563 from Oncogene, EST21-A from Alpha Diagnostics and code 582005 by Calbiochem and the monoclonal murine antibody clone 44F12 by NovoCastra. We also introduced further antihTERT antibodies. To visualize the outcome we performed the alkaline phosphatase anti-alkaline phosphatase (APAAP, 56) for the current study, as it had proved successful in our earlier immunohistochemical examinations (57) (58) (59) . The APAAP was more suitable in our study of hTERT evidence than EnVision™ (DakoCytomation, Denmark) (52) . After methanol and acetone fixation, the slides with the frozen sections were pretreated for 30 min in a steamer (95-99˚C) in TRS buffer (target retrieval solution) S1699 (Dako Cytomation). All anti-hTERT antibodies and all control antibodies used in the study were pretreated in the same way. Pretreatment in the steamer proved the most effective for the nuclear presentation of hTERT in frozen sections.
All incubation steps taken in the immunohistochemical staining process were performed in a humidified chamber. To block non-specific reactions we incubated sections at room temperature for 20 min with the ready-made X0909 blocking buffer (DakoCytomation). Between each step the sections were rinsed thoroughly three times in TBS buffer, pH 7.6 (Tris buffered saline, concentrated 10x, S3001 DakoCytomation; with pH of dilution at 7.6).
All antibodies were diluted in S2022 (DakoCytomation, ready to use). We determined the optimal dilution for each antibody in accordance with the product data sheets. Antibodies were incubated for 60 min at 37˚C in the drying oven and then for 30 min at room temperature. Table II lists the eleven anti-hTERT antibodies and the four primary control antibodies. In the case of some antibodies only a limited number of tissues were stained.
The APAAP (56) used to present the antigen antibody reaction was carried out as follows: The two bridge antibodies were incubated at room temperature at 1:40 (diluted in antibody dilution plus 5% AB serum by Biotest AG, Dreieich, Germany; Cat. 805135). For sections with polyclonal primary antibodies (Table II : Ab 1, Ab 2, Ab 4 to Ab 9 and Ab 13) monoclonal mouse anti-rabbit bridge antibody (DakoCytomation M0737) were applied and for sections with monoclonal antibodies (Table II: Ab 3, Ab 10, Ab 11, Ab 12, Ab 14 and Ab 15) polyclonal rabbit anti-mouse bridge antibody (DakoCytomation Z0259) were used. Sections were then incubated for 40 min with the monoclonal APAAP complex (DakoCytomation D0651), diluted 1:100 in antibody dilution plus 5% inactivated fetal calf serum (FKS, Biochrom AG, Berlin, S0115, Germany). Substrate development lasted approximately 20 min (gauged by visual judgment) with DakoCytomation K0624 substrate plus 2 additional drops of levamisole (K5000 by DakoCytomation) per 3 ml of substrate. The sections were counterstained with hemalaun (DakoCytomation S2020) for 5 min with subsequent blueing for 5 min in tap water.
The results of immunohistochemistry were interpreted with control antibodies (Table II) : Ki-67 (Ab 12) to prove proliferation and for better recognition of basal cell carcinomas in the small frozen sections, and CD45 (Ab 14) for better visualization of lymphocyte mononuclear infiltration. In previous examinations we had only been able to prove a limited correlation between telomerase activity and lymphocyte infiltration in tumor margin tissues (24, (60) (61) (62) (63) . We expanded our investigation and incorporated an anti-nucleolin antibody (Ab 13) to clarify this issue since the monoclonal anti-hTERT antibody (clone 44F12, code NCL-hTERT, Table II , Ab 3) was classified in the paper by Wu et al (64) as an antibody against nucleolin.
In addition to characterize BCC (24) we used a monoclonal antibody against mutated p53 Ab-3 (Ab 15, Table II) . To ensure the reliability of our immunohistochemical stainings we ran a parallel assay with a negative control for each staining (negative control sera mouse DAKO code N1698, Table I . Characterization of the 41 patients with a basal cell carcinoma.
Sex/age a (years )  Tumor site  Tissue source  Tumor spead  Histopathology  -----------------------------------------------------------------------------------------------------1  M/53  eye  TC  T1  nodular  2  M/82  eye  TC  T1  nodular  3  M/51  eye  TM  T1  nodular  4  M/38  eye  TC  T2  nodular  5  M/67  eye  TC  T1  nodular-sclerodermiform  6  F/86  eye  TM  T1  sclerodermiform  7  F/60  lips  TC  T1  nodular 
a Age at tissue harvesting; TC, tumor center; TM, tumor margin; T1, maximal tumor spread 20 mm; T2, tumor spread >20 mm, TNM classification (55).
- (64) ]. 
negative control sera rabbit DAKO code N1699; ready for use). These contol sera were constantly negative.
The score values for hTERT, Ki-67, nucleolin and p53 refer exclusively to nuclear and/or nucleolar stainings in the carcinomas or squamous epithelia. The expression of CD45 was evaluated in the whole tissues. In analogy to our previous immunohistochemical studies with other antibodies (57-59) we used the immunohistochemical evaluation by Remmele et al (65) (66) and two independent observers calculated the score values. Evaluation of the sections was performed three times and was based on estimated values for staining intensity (SI: 0, no staining; 1+, weak; 2+, moderate; 3+, strong and 4+, very strong staining) and percentage of positive staining in tissue sections (PP: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3, 51-75% and 4, 76-100% positive cells). The immunohistochemical score value (IRS) was then calculated by multiplication of SI and PP. The evaluation was performed with a 40-fold objective.
Determining telomerase activity in the same frozen tissue samples. As described above (24, 26, 49, (62) (63) , we used the test kits TeloTAGGG Telomerase PCR ELISA (Roche Diagnostics -Applied Science, Mannheim, Germany, catalog no. 11854666910) and TeloTAGGG Telomerase PCR ELISA Plus (Roche Diagnostics -Applied Science, catalog no. 12013789001) for demonstration of telomerase activity. The frozen tissues were lysed, the lysate adjusted with the addition of 0.5 and 5 μg protein or, if necessary, amounts under 0.5 μg with PCR. We conducted the examination following suppliers' instructions. It was necessary to use the TeloTAGGG Telomerase PCR ELISA Plus kit because its internal standards make it possible to check for any false negative findings caused by inhibition of the PCR. With a subsequent ELISA it was then possible to detect telomerase activity in mOD.
In earlier studies (24,62) we had worked out an evaluation scheme: we classified the telomerase activity, measured in mOD, into five groups: 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; 2+, TA 450-750 mOD; 3+, TA 750-1050 mOD; 4+, TA above 1050 mOD.
Statistical evaluation. For statistical evaluation, SPSS 15.0 for Windows, Version 15.0.1 (22 November 2006) was available (67) . We used the script of the Charité Institute for Biomathematics and Biometry for Human Medicine (68) and Sachs (69) . Apart from the descriptive statistics, we compared median values using the Mann-Whitney U-test or, Table II . Continued. 
aa, amino acid; Ab, antibody; KLH, keyhole limpet hemocyanin.
if distribution was normal, we compared mean values using the t-test. Test results for difference with p<0.05 were rated as statistically significant.
To determine the relation between the telomerase activity and the immunohistochemical score values we applied the two-sided Spearman's rank correlation coefficient (Spearman's rho). If the result was above the tabulated value of 0.05 there is a correlation between the measurements examined. We tested for their interdependence. We applied the Fisher's exact test considering the small number of tissue specimens. Given the relatively low number of patients, we reduced all values into two groups for the statistical comparison of incidence (immunoreactive score values and telomerase activity) in the Fisher's exact tests. We divided all values into group 0 and group 1: for group 0 values < median value and for group 1 values ≥ median value. The median value was chosen as the cut-off value because the score values were not normally distributed.
For testing the prognostic statement made by these values in the Kaplan-Meier curves we used the patient outcome documentation in our hospital. We recorded the number of months between tissue excision and relapse or secondary basal cell carcinoma. We applied two hTERT groups to the Kaplan-Meier curves. The difference of the curves compared was significant when log-rank test proved p<0.05.
Results

Expression of hTERT in basal cell carcinoma tissue samples.
The data of patients with a basal cell carcinoma, all of which were collected after patients' consent, are summarized in Table I . We investigated hTERT expression in these tissues with the eleven anti-hTERT antibodies (Table II) . With Ab 1 (polyclonal anti-telomerase code PC 563) and Ab 5 (polyclonal anti-TERT H-231, code sc-7212) the immunohistochemical hTERT scores were lower (or negative) than with the other nine antibodies. We therefore applied these antibodies only for some sections and did not document these results in detail.
Table III summarizes the telomerase activity and immunoreactive hTERT score values found in the basal cell carcinoma tissues. With Ab 2 and Ab 6 the hTERT scores were particularly low (Fig. 1) , with Ab 6 they were higher than with Ab 2 (p=0.091). The order of succession of the median hTERT scores in BCC tumor center tissues was Ab 4=Ab 7, Ab 3=Ab 11, Ab 8, Ab 10, Ab 9, Ab 6 and Ab 2. Fig. 1 shows the median score values for hTERT expression and for the control antibodies (Tables III and IV) in basal cell carcinomas and in squamous epithelia of the same tissues. The figure reveals that the polyclonal antibody anti-EST2 (code EST21-A, Ab 2, Table II ) and the antitelomerase Ab code 582000, Ab 6 (Table II) were the antibodies least suited for demonstrating hTERT in frozen tissues. In the comparison of the higher hTERT scores in BCC in tumor center tissues rendered by Ab 3, Ab 4 and Ab 7 to Ab 11 (U-or t-test: p between 0.204 and 0.942) only between Ab 7 and Ab 9 was there a difference which even approximated significance (p=0.088). Table IV summarizes the immunoreactive score values in the BCC-free squamous epithelium in tumor center tissue samples. Immunohistochemistry was done only with antihTERT Ab 2 to Ab 4 and Ab 6 to Ab 7 (Table II) . The U-test rendered score values for anti-hTERT antibodies Ab 2 to Ab 4 and Ab 6 to Ab 7 which were higher in tumor center tissues than in squamous epithelium of the same tissue sample, with Ab 4 significantly higher (p=0.015).
We also investigated the expression in basal cell carcinomas of the four control antibodies, of anti-Ki-67 (Ab 12), anti-nucleolin (Ab 13), CD45 (Ab 14) and anti-mutated p53 (Ab 15, Table II ) and summarize the scores with the control antibodies in Tables III and IV. Contrary to the significant difference between the expression of Ki-67 and CD45 (p=0.007) neither in the statistical comparison (U-or t-test) of the immunoreactive score values between Ki-67 (Ab 12) and anti-nucleolin (Ab 13) (t-test: p=0.261) nor between CD45 (Ab 14) and antinucleolin in BCC were there significant differences (U-test: p=0.140). Notably, the Ki-67 (Ab 12) scores are significantly higher in the basal cell carcinoma than in squamous epithelium of the tumor center tissues: p=0.032 (U-test). Finally, the score values of mutated p53 were not significantly higher in the tumor center tissues than in squamous epithelium of the tumor center tissues (t-test: p=0.213). In BCC tissues the difference between the score values by Ab 3 (code NCL-LhTERT) and Ab 13 (anti-nucleolin antibody, Table II) were not significant (n=8: p=0.259). According to Wu et al (64) NCL-L-hTERT has the characteristics of an anti-nucleolin antibody.
Using the Fisher's exact test we explored whether hTERT expression in BCC corresponded with telomerase activity in the same tissues (Table III) . Once again we formed two groups (see 'Patients and methods'). The test revealed a statistical correlation with telomerase activity: between p=1.000 (hTERT expression shown by Ab 2, Ab 4, Ab 9 and Ab 3) and p=0.101 (expression revealed by Ab 6, Table II ).
These results did not correspond to the examination by Spearman's rank correlation coefficient with the exact hTERT scores and telomerase activity in mOD. As demonstrated in some examples this might be due to the heterogeneous distribution of data: Fig. 2 .
Using the Fisher's exact test we also addressed the question of whether there is a relationship between the telomerase activity in the whole tumor center tissues and the immunoreactive hTERT scores in the squamous epithelia of the tumor center tissues (Table IV) . None of the comparisons were significant (p-value range 0.192-1.000), so that a correlation between telomerase activity and hTERT score values can be assumed. The Spearman's rank correlation coefficients showed no correlation between the telomerase activity in mOD and the exact hTERT scores.
There was a statistical correlation between telomerase activity and expression of the control antibodies. Table I ) and CD45 in the whole tissues: immunoreactive score values (IRS). . TA IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  Ab 2 Ab 3 Ab 4 Ab 6 Ab 7 Ab 8 Ab 9 Ab 10 Ab 11 Ki-67 Ab 13 CD45 p53 (Table II) ; -, not examined. Table IV . Telomerase activity and expression of hTERT, Ki-67 (Ab 12) and p53 (Table II) in squamous epithelia from tumor center tissue samples (immunoreactive score values, IRS). .  TA  IRS  IRS  IRS  IRS  IRS  IRS  IRS  Ab 2  Ab 3  Ab 4  Ab 6  Ab 7  Ab 12 p53 
TA, telomerase activity; 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; 2+, TA 450-750 mOD; 3+, TA 750-1050 mOD; 4+, TA above 1050 mOD; Ab, (Table II) ; -, not examined or no squamous epithelium present in section.
- et al (64) yielded no significance (p=0.559) compared to the anti-nucleolin scores.
Expression of hTERT in tumor-free resection margin tissue of the BCC. Table V summarizes the immunoreactive hTERT scores for BCC-free tumor margin tissue containing squamous epithelium. Table I shows patient data, Fig. 3 the median values of the immunoreactive scores.
The same two polyclonal antibodies anti-EST2 (Ab 2) and anti-telomerase code 582000 (Ab 6, Table II) which had shown the lowest hTERT scores in all tumor center tissues of our study (Fig. 1) , also showed the lowest hTERT scores in the squamous epithelia of BCC-free tumor margin tissue (Fig. 3) . With all antibodies, expression in squamous epithelium in the tumor center was usually higher than or equal to that in the tumor margin tissue (U-test: p-value range 0.184-0.977). All squamous epithelial hTERT score values from the tumor margin were lower than those in tumor center tissues and significantly lower with Ab 3, Ab 4 and Ab 7 (U-test p=0.019, p=0.003, respectively, p<0.001).
The highest score values were presented by the squamous epithelium from the tumor tissue sample and the tumor margin with Ab 3 (NCL-hTERT), but the score values with Ab 4 and Ab 7 were not significantly lower (in the tumor center tissues: p between 0.186 and 0.737, in the tumor margin tissues: p-value range 0.479-0.886).
The hTERT scores of squamous epithelium in the center of basal cell carcinomas and of the BCC-free tumor margin did not differ significantly from the scores for Ki-67 (p=0.235) and for p53 (p=0.461) in the U-test, while Ki-67 scores presented no significant difference in the tumor center tissue (p=0.089 and p=0.095).
Using the Chi-square test (or Fisher's exact test) we tested for a correlation between hTERT expression in the squamous epithelium of BCC-free tumor margin and telomerase activity in the tumor margin (p-value range 1.000-0.153) and for a correlation between the CD45 score values in the same tissue and hTERT expression (p-value range 0.622-0.118). We found a connection with all parameters. This, however, was not confirmed by Spearman's rank correlation coefficients Table V . Telomerase activity, expression of hTERT, Ki-67 and p53 in squamous epithelia of the tumor-free tumor margin of basal cell carcinomas (patient data in Table I ) and of CD45 in the whole tissues of tumor margin tissues. No.  TA  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  Ab 2  Ab 3  Ab 4  Ab 6  Ab 7  Ki-67  CD45  p53  - 
-----------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------
TA, telomerase activity; 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; 2+, TA 450-750 mOD, 3+, TA 750-1050 mOD; IRS, immunoreactive scores; Ab, antibody (Table II) ; -, no squamous epithelium in section.
-----------------------------------------------------------------------------------------------------
which rendered no correlation between telomerase activity in mOD and the exact scores values. Table VI ; median values are illustrated in Fig. 3 . Fig. 3 also illustrates the low sensitivity of antibodies Ab 2 and Ab 6 (Table II) , disqualifying them for detection of hTERT expression in squamous epithelia from control tissues. The immunoreactive scores of control tissue samples were very heterogeneously distributed in the squamous epithelium itself and varied with the individual antibody. We compared the hTERT-scores in the U-test (or the t-test). Statistically the scores with Ab 2 were significantly lower than those with Ab 3, Ab 4, Ab 9 to Ab 11 (p<0.001-p=0.04); with Ab 6 significantly lower than with Ab 3 (p<0.001), and with Ab 7 significantly lower than with Ab 10 (p=0.034). The scores with Ab 6 were higher but not significantly higher than with Ab 2 (p=0.368). The highest hTERT scores in extraoral control tissues were with Ab 11, Ab 9, Ab 10 and Ab 4, Ab 3, Ab 7, Ab 8, Ab 6 and Ab 2 (note that this successive order is the inverse of that registered in BCC tissues). Most of the score values between the Ab 3 to Ab 4 and Ab 7 to Ab 11 in squamous epithelia of control tissues were not significant (U-or t-test: p-value range 0.159-0.966). However, score values with Ab 7 were significantly higher than with Ab 10 (p=0.034), and nearly reached significance with Ab 11 (p=0.054) and Ab 9 (p=0.082).
Expression of hTERT in extraoral control tissues. Resulting immunoreactive hTERT score values for 14 extraoral squamous epithelia are listed in
The scores of Ki-67, CD45 and p53 are significantly lower in the squamous epithelia of the extraoral control tissues than in the BCC tissues (U-test: p<0.001, p=0.034 and p=0.001).
In the Fisher's exact test there was a connection between telomerase activity in the control tissues and the hTERTscore values as well as between telomerase activity in the control tissues and the scores for control antibodies (all pvalues were >0.05). However, proof of exact score values with telomerase activity in mOD using Spearman's rank coefficients showed no correlations.
Localizing hTERT with selected anti-hTERT antibodies.
The distribution of hTERT-positive cells was usually very heterogeneous in the individual basal cell carcinomas irrespective of the antibody used (Table III) . In some basal cell carcinomas, however, distribution of positive cells was restricted to the peripheral area of the carcinoma. Where squamous epithelium in tissues from tumor patients or in control tissue was still normal, the hTERT-positive cells were limited to one or two basal layers. However, in hyperplastic or more or less severely dysplastic squamous epithelium, suprabasal hTERT was also evident or was spread over the entire squamous epithelium. Fig. 4 shows some of the immunohistochemical images collected in these studies comparing the patterns of expression as indicated by the individual anti-hTERT antibodies after pretreatment of the frozen sections in the steamer and visualization by APAAP (56) .
Prognostic significance of immunohistochemical proof of hTERT protein in BCC tissues.
In order to determine the prognostic significance of hTERT expression we drew Kaplan-Meier curves as described under 'Patients and methods' for each antibody in the carcinoma tissue, in the squamous epithelium of tumor center and tumor margin tissue (Tables III and IV) . Data were obtained from the patient documentation in our clinic. Most of the KaplanMeier curves rendered no significant correlation between increased hTERT expression and poor prognosis. Only patients with higher hTERT scores (higher than the median value) in the tumor center (Fig. 5A ) and tumor margin tissues (Fig. 5B) as demonstrated with Ab 4 displayed a longer period without recurrence: The mean time period before relapse for those patients from whom tumor center tissues were examined was 13±2 months (IRS<median) to 51±5 months (IRS ≥ median): Log-rank test p=0.008. For patients from whom tumor margin tissues were examined it was 25±10 months (IRS < median) to 82±25 months (IRS ≥ median): log-rank test p=0.056.
Discussion
After Kim et al (37) developed the TRAP (telomeric repeat amplification protocol) it became possible to demonstrate telomerase activity in larger studies of various tumors. Since then many researchers have applied this protocol for proof of telomerase activation in basal cell carcinomas (23, 24, 26, (38) (39) (40) (41) 45, 47, 48, 50) . Up to now only a few studies with in situ localization of hTERT in BCCs have been published: immunohistochemical studies by Park et al (25) , Brasnac et al (70) and Perrem et al (71) , an in situ hybridization study by Guttman-Yassky et al (72) and a fluorescence in situ hybridization study by Perrem et al (71) . Immunohistochemical investigations on cryo sections are missing altogether.
In the present study we applied immunohistochemistry with commercial antibodies for the in situ demonstration of telomerase activation in frozen sections from basal cell 
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carcinoma of the head and neck (Table I) and to compare them with extraoral control tissues from patients without tumor. In previous studies with these same carcinoma tissues and BCC-free tumor margin tissues we had proved telomerase activity by PCR ELISA (24, 26, 49) . In this study we wanted to clarify in the same frozen tissues which cells were responsible for the telomerase activity in the tumor margin and in tissues from patients without tumor. We were obliged to use commercial antibodies (Table II) .
Methodical procedure and assessment of nuclear demonstration of hTERT on frozen sections from basal cell carcinomas: As already reported (52) we optimized the immunohistochemical nuclear hTERT proof in the basal cell carcinoma and tumor margin tissues with antibodies Ab 1-Ab 4 (Table II) and applied the same method of pretreatment and detection for further anti-hTERT antibodies Ab 5 to Ab 11 and also for the control antibodies (Ab 12 to Ab 15, Table II) . We used the same immunohistochemical method, the same Figure 5 . Outcome in patients with a basal cell carcinoma (Table I ) and hTERT score values with the polyclonal antibody Ab 4 (code 582005) in the tumor center and tumor-free margin tissues: Kaplan-Meier curves for tumor center tissues: log-rank test p=0.008; the mean time period until relapse in 15 patients with hTERT score value ≥ median value in carcinoma was 51±5 months, in 10 patients with score value < median value 13±2 months; Kaplan-Meier curves for tumor margin tissues: log-rank test p=0.056; the mean time period until relapse in 13 patients with hTERT score value ≥ median value was 82±25 months, in 4 patients with score value < median value it was 25±10 months. 
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pretreatments of the frozen slides and the same anti-hTERT antibodies as when we investigated squamous cell carcinoma tissues, Fabricius et al (52) . Conforming to Yan et al (73) no unambiguous nuclear staining was produced with the polyclonal antibody code PC563 by Oncogene/Calbiochem, an antibody against the hTERT amino acid sequence 348-358 (our Ab 1). We abandoned this antibody. With the other three antibodies, the two polyclonal antibodies code EST21-A (Ab 2) and code 582005 (Ab 4) and the monoclonal NCL-L-hTERT (clone 44F12, Ab 3) we worked out the best immunohistological localization of hTERT in the nuclei of the frozen sections. In paraffinembedded tissues or cells Hiyama et al (74) , Poremba et al (75) (76) (77) , Yan et al (73) and Park et al (25) obtained successful nuclear demonstration for hTERT. To achieve nuclear staining in frozen sections, methanol-acetone fixation followed by pretreatment in a steamer in a slightly acidic buffer proved the most suitable method. In paraffin sections Taylor et al (78) applied various antibodies, either without pretreating the sections or after pretreatment in the microwave, autoclave and steamer. Steamers have been used only rarely for frozen sections (79) and up to now not at all for anti-hTERT antibodies. Without pretreatment in the steamer only a few isolated cells presented nuclear staining with all hTERT antibodies used by us and staining was predominantly cytoplasmic or negative. Notably, pretreatment of the frozen sections was not crucial for our control antibodies Ab 12-Ab 15 (Table II) .
For the assessment of the semiquantitative immunoreactive hTERT scores (65,66) we included only nuclear antibody marking (Table III to Table I . We demonstrated hTERT in varying levels in the carcinomatous and in carcinoma-free tumor margin tissue (Tables  III-V and Figs. 1-3, 4A-F) . In these tissues, the score values with the antibodies EST21-A (Ab 2, Table II ) and code 582000 (Ab 6) were the lowest. This result is in accordance with our earlier examination of tissues from squamous cell carcinomas (52) . The other antibodies, Ab 3, Ab 4 and Ab 7-Ab 11, showed clear nuclear (or nucleolar) marking of carcinoma cells and squamous epithelial cells.
To date only one immunohistochemical study by Park et al (25) is available in which the antibody code 582005 (Ab 4, Table II) Saleh et al (50) demonstrated significantly lower hTERT in the tumor margin than in the respective BCC, again using real-time PCR. In our study, telomerase activity as demon- Table VI . Telomerase activity and expression of hTERT, Ki-67 (Ab 12), nucleolin (Ab 13) and CD45 (Ab 14) in extraoral squamous epithelia of 14 control tissues (IRS). . TA IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  IRS  Ab 2 
Co, control-No.; TA, telomerase activity; 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; Ab, antibody: Table II ; IRS, immunoreactive scores; -, not examined or no squamous epithelium in section; a TA 187 mOD; tissue from nose/nostril.
-----------------------------------------------------------------------------------------------------
strated in tumor center tissue was also distinctly, but not significantly higher than in tumor margin tissue (p=0.095). It corresponded to the decreased hTERT score values of the tumor margin tissues (Tables III-V and Figs. 1 and 2 ). On the other hand, lymphocytic infiltrates detected in the tumor margin tissues (CD45 IRS scores Tables III and V) were only slightly higher than in tumor center tissues (p=0.838).
We correlated proof of hTERT in BCC tumor and tumor margin tissues with recurrences in Kaplan-Meier curves. Two Kaplan-Meier curves, one with higher and the other with lower hTERT expression ('Patients and methods'), diverged with significance or approximate significance, despite the ambiguity associated with the presence of many censored cases, when the code 582005 antibody (Ab 4, Table II ) was used: log-rank test p=0.008 (tumor center) and p=0.056 (tumor margin), Fig. 5A and B. Altogether, the period without relapse was significantly longer when hTERT expression was higher. These results are contrary to our hTERT results in tissues from squamous cell carcinoma (52) .
Comparison of hTERT results in basal cell carcinomas and squamous cell carcinoma of the head and neck.
In the earlier study (26) we compared telomerase activity in BCC tissues (26/30=87%) and in extraoral squamous cell carcinoma tissues (9/12=75%) from the same region. Our results conformed with those of a review article by Dhaene et al (42) : Telomerase activity was detected in 81% of BCC tissues (21/26) and in 50% extraoral SCC tissues (9/18) . This deviated from the results of Boldrini et al (48) , who found high telomerase levels only in 35% of BCC tissues (7/20) and 75% of SCC tissues (9/12). In comparison with this hTERT study with basal cell carcinoma tissues and our earlier hTERT study with both oral and extraoral squamous cell carcinoma tissues (52) telomerase activity in the BCCs with the median value of 534 mOD was significantly lower than in the HNSCC tissues with the median value of 999 mOD (p=0.012) and about significantly lower in the BCC tumor margin tissues with median value of 65 mOD than in the HNSCC tissues with median value of 331 mOD (U-test p=0.076).
The aggressive growth for HNSCCs was reflected only by the higher telomerase activity in HNSCC tissues and not by the hTERT score values (52) . From the score data in the immunohistochemical hTERT study with squamous cell carcinoma tissues (52) and in this study with BCC tissues it is clear that particular antibodies are more suited for hTERT proof on SCCs and BCCs, respectively. Contrary to these results, the scores with Ab 7 (code ab177) were significantly higher in the BCC tumor center tissues than in HNSCCs (U-test p=0.023). Despite the identical hTERT median score value with Ab 4 (code 582005), there were no significantly higher score values in BCC than in HNSCC (p=0.206): The hTERT results of Kaplan-Meier curves with BCC tissues are doubtful due to the many censored cases (Fig. 5A  and B) , as opposed to different Kaplan-Meier curves of hTERT results in HNSCC tissues (52) . The high hTERT scores of HNSCC tissues correspond with shorter periods without relapse, but not significantly.
Immunohistochemical proof of hTERT in extraoral control tissues. In this study we compared the hTERT scores of BCC tissues only (Tables III and V, Figs. 1-3 ) with hTERT scores of 14 extraoral control tissues with squamous epithelia (Table VI and Fig. 3 ) from 14 patients without tumor. Telomerase activity was significantly lower in the control tissues than in BCC center tissues (p<0.001); it was not significantly lower than in BCC margin tissues (p=0.372). The squamous epithelium of the control tissues was normal only in part, having been harvested from inflamed tissue or from tissue which was hyperplastic or to varying degrees dysplastic. The hTERT expression in squamous epithelia of control tissues was localized in the basal to parabasal layers, and over the entire epithelium of dysplastic squamous epithelium as well as in squamous epithelia from BCC tissues.
Hiyama et al (74) , on the other hand, were able to give immunohistochemical evidence in paraffin sections of hTERT expression in a series of normal cells using the anti-EST2 antibody (in our study Ab 2): in basal keratinocytes of the skin, in basal cells of the endometrium and in epithelial cells from the mamma. Using the monoclonal NCL-hTERT (our Ab 3), according to Wu et al (64) an anti-nucleolin antibody, Luzar et al (82) found the lowest hTERT expression in normal larynx epithelium from control persons (mean hTERT index 0.17) in comparison to increasing expression in hyperplastic tissue (mean hTERT index 0.44), in basal hyperplasia (mean hTERT index 0.54) and atypical hyperplasia (mean hTERT index 0.91). Volpi et al (83) reported nuclear, nucleolar and cytoplasmic staining of hTERT with a monoclonal antibody Tel 366-10 in normal tissue from skin (among other tissues). With immunohistochemical methods Park et al (25) revealed hTERT expression with the polyclonal antibody by Calbiochem (code 582005, in our study Ab 4, Table II) in 6/10 actinic keratoses. Hu et al (47) were unable to detect hTERT in 5 tissues from normal skin by RT-PCR and, likewise, Ogoshi et al (81) showed low levels or no hTERT with in situ hybridization in 7 protected skin tissues. They did, however, find hTERT expression in all 8 sun-exposed skin tissues. (38) identified telomerase activity in 67% of BCC tumor margin tissues examined.
We posed the question of whether the presence of telomerase activation was conditioned by lymphocytic infiltration in the tumor margin or in control tissues and whether there was a higher telomerase expression, indicating field cancerization, in the region surrounding the tumor (28) (29) (30) (31) . Telomerase activity was identified in activated lymphocytes (60, (84) (85) (86) and in an attendant lymphocytic infiltration (87,88) described in BCC tumor margin (38, 87) . In earlier studies we detected a lymphocytic infiltration by histopathology in 12 of 27=44% (24) and in 13 of 25=52% (49) tumor margin tissues and in 2/14=14% (49) extraoral control tissues. In this study we applied a monoclonal CD45 antibody (Ab 14, Table II ) to evaluate lymphocytic-monocytic infiltrates in tumor margin and control tissues: Tables V and VI. Statistical comparison revealed a significant variation between the CD45 scores and the extremely low hTERT score values with antibody Ab 2 (Table II) in the tumor margin (p=0.002) and with both antibodies Ab 2 and Ab 6 (Table II) in control tissues (p=0.016 and p=0.043). We also demonstrated isolated hTERT marked cells in the stroma of these tissues.
In an earlier study (49) using histopathological methods we detected field cancerization surrounding the BCC (28-31) after UV radiation with the solar elastosis in 15 of 27 (58%) tumor margin tissues. The tumor margins were histopathologically BCC-free. In squamous epithelial cells of tumor margins hTERT was expressed distributed in the basal as well as in the suprabasal layer. hTERT expression was highest with the antibodies (in successive order of the median values) Ab 4=Ab 7, Ab 3 (Table V and Fig. 3 ). In the exact Fisher's test we registered a correlation between hTERT scores and telomerase activation. Ab 4 (code 582005) and Ab 7 (code ab177) were appropriate for sensitive hTERT detection of field cancerization in BCC-free resection margin tissues.
The controversial NCL-hTERT antibody (64) , Ab 3 of our study, was also suitable for hTERT detection in frozen sections both in tumor margin and in tumor center tissues. This antibody has been applied by many authors in recent years to demonstrate hTERT in many tumors. Wu et al (64) summarize the most important work done up to 2006 but criticize the use of the NCL-L-hTERT for immunohistochemical demonstration of hTERT. From their investigations of the antibody they concluded that the antibody NCLhTERT targets to nucleolin, rather than hTERT. In our immunoabsorption study with squamous cell carcinoma (52) we tested the anti-hTERT antibody specificity of our antihTERT antibodies Ab 3 to Ab 4, Ab 7 to Ab 11 and of the anti-nucleolin antibody Ab 13 (Table II) with two hTERT peptides and with a nucleolin peptide (52) . The results showed that Ab 3 (NCL-L-hTERT antibody) was not absorbed any more with the nucleolin peptide than were the other anti-hTERT antibodies. In agreement with other researchers (27, 70, 71, (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) and despite the objection raised by Wu et al (64) the Ab 3 proved suitable for hTERT detection. Mitsuishi et al (98) not only confirmed the consideration of Wu et al (64) , but also found excellent correlation between nucleolin expression and telomerase activity levels in Bowens's disease and in normal sunexposed skin. In the immunohistochemical study of Ridley et al (99) hTERT expression in ependymomas with Ab 3 showed very strong correlation with the outcome in pediatric intracranial ependymomas (95) . Furthermore, Khurts et al (100) revealed experimentally that nucleolin interacts with telomerase and changes its subcellular localization. In this process it can bind with hTERT, with significant consequences for its own nucleolar localization (94,100). Lam et al (89) proved with an immunohistochemical study in paraffin sections of colorectal carcinomas and the NCL-L-hTERT antibody that telomerase and nucleolin interact with one another and display the same intracellular distribution. Lam et al concluded that despite the criticism of Wu et al (64) telomerase activity can also be demonstrated with this antibody NCL-hTERT.
We did not apply anti-hTERT antibodies Ab 8 (code ab23699), Ab 9 (code 600-401-252), Ab 10 (code NB 100-297) and Ab 11 (code NB 100-317, Table II ) to tumor margin tissues. But in frozen sections they showed intense nuclear and/or nucleolar marking in basal cell carcinoma (Table III and Fig. 4A-F ) and in squamous epithelium of the tumor center (Table III and Fig. 1 ). The polyclonal antibodies code EST21-A (Ab 2) and code 582000 (Ab 6, Table II) displayed the weakest nuclear staining in frozen sections of our examinations (Tables III-VI, Figs. 1 and 3 ). With the Ab 2 Hiyama et al (74, (101) (102) (103) (104) achieved strong nuclear hTERT staining on paraffin-embedded cells and biopsies. Miyazu et al (103) also demonstrated pronounced hTERT expression on paraffin sections from lung tumors and normal lung squamous tissue. The EST21-A antibody attained significant demonstration of hTERT in 23 patients with histopathologically normal epithelium: patients with higher hTERT expression in epithelial tissue developed lung carcinomas. With the polyclonal antibody code 582000 from Calbiochem (Ab 6, Table II) background staining was markedly weaker than with antibody code 582005 (Ab 4) from the same firm. Just as with hTERT scores of Ab 2 (code EST21-A), however, values with Ab 6 were much lower than those with other antibodies (Figs. 1 and 3) .
Viewing critically our immunohistochemical results for hTERT expression in BCC tissues we shall verify our experimental procedure with a larger patient population. According to proposals put forwarded by Tao et al (105) it might be regarded for an adjuvant hTERT-targeted therapy. In the first clinical trials by Mavroudis et al (106) and Bolonaki et al (107) the introduction of the TERT (572y)-peptides was put to practice. In a clinical phase I/II study Brunsvig et al (108) tested two hTERT vaccines (GV1001 against hTERT sequence 611-626 and HR2822 against hTERT sequence 540-548): 12 of 24 patients and in addition, two patients after booster injections developed an immune reaction. The authors suggested that further clinical studies were warranted to evaluate this hTERT-based vaccination. After evaluation of all studies carried out so far with the hTERT 540-548-peptide Wenandy et al (109) gave notice that, despite contradictory outcomes, this peptide can be a target for tumor lysis therapy. Moreover, for assessment of their adjuvant BCG immunotherapy antibody NCl-hTERT (our Ab 3) was applied for evidence of hTERT as a therapeutical mark in patients with bladder carcinoma (97) .
